The Effects and Safety of Gamma Rhythm Stimulation on Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 40855942 · doi:10.1177/15459683251360733
What was done
A systematic review and meta-analysis searched PubMed, Web of Science, Ovid-Embase, and Ovid-MEDLINE through April 2024 for randomized controlled trials evaluating gamma rhythm stimulation (notably 40 Hz brain or sensory stimulation) on cognitive function and safety in Alzheimer's disease. Cognitive outcomes included the Face-Name Association Test (FNAT), Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), and Montreal Cognitive Assessment (MoCA).
What was found
Eight studies comprising 291 participants were analyzed. Pooled effects favored gamma stimulation for cognitive measures: FNAT (SMD = 3.76, 95% CI: 2.52 to 4.99; I² = 65%), MMSE (SMD = 3.09, 95% CI: 2.37 to 3.82; I² = 0%), ADAS-cog (SMD = -4.16, 95% CI: -6.60 to -2.62; I² = 0%), and MoCA (SMD = 2.17, 95% CI: -0.54 to 4.88; I² = 0%). Adverse events showed no statistically significant difference versus sham (P = .06).
Why it matters
This review compiles the available randomized trial evidence for 40 Hz gamma stimulation in Alzheimer's disease, showing early signals of cognitive enhancement with an acceptable safety profile.
Limits
The total sample size was small (291 participants across 8 studies, averaging ~36 patients per trial). Standardized mean differences greater than 3.0 to 4.0 are extraordinarily large for clinical dementia trials and strongly suggest small-study effects or publication bias. The confidence interval for MoCA crossed null.
Cited by
- supports 40 Hz sensory stimulation enhances gamma brainwave activity and has shown early clinical signals associated with slower cognitive decline.
- supports Exposure to 40 Hz sensory stimulation increases brain gamma activity and has been reported in early clinical research to be associated with slower cognitive decline in some participants.